Zenas BioPharma Quarterly Cash Flow Statement
NASDAQ: ZBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
27.26+1.02 (+3.89%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zenas BioPharma free cash flow
In the quarter ended Jun 30, 2026, Zenas BioPharma generated -$57.2 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$57.2 million, a free-cash-flow margin of -5723.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Zenas BioPharma cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -111.46M | -80.99M | -240.44M | -51.50M | -52.22M | -33.57M | -52.60M | -38.61M | -37.98M | -27.80M | -24.59M | 35.61M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | -208.42% | — | — | — | — |
| Depreciation & Amortization | 4.00K | 6.00K | 10.00K | 11.00K | 12.00K | 23.00K | 33.00K | 36.00K | 35.00K | 33.00K | 30.00K | — |
| Stock-Based Compensation | 8.62M | 9.20M | 7.58M | 7.34M | 6.04M | 5.39M | 5.50M | 2.84M | 1.54M | 947.00K | 1.14M | 1.00M |
| Change in Working Capital | 7.71M | -9.65M | 8.56M | -3.45M | 5.38M | -8.64M | 9.11M | 5.20M | 6.27M | 5.53M | 7.72M | — |
| Operating Cash Flow | -57.24M | -75.20M | -52.41M | -41.13M | -41.74M | -37.05M | -38.55M | -31.06M | -30.96M | -19.10M | -15.40M | — |
| Capital Expenditures | 0 | -2.00K | 0 | 0 | 0 | -18.00K | -74.00K | 0 | -35.00K | -22.00K | — | — |
| Investing Cash Flow | -287.70M | 31.61M | -93.36M | 40.04M | -112.29M | -86.27M | -3.73M | -26.76M | -35.00K | -22.00K | — | — |
| Debt Issued | — | — | 0 | — | — | — | — | — | — | — | — | — |
| Financing Cash Flow | 42.06M | 433.48M | 140.84M | 72.62M | 1.72M | 99.00K | 1.85M | 233.98M | 177.74M | -614.00K | 50.00K | — |
| Net Change in Cash | -303.65M | 389.58M | -4.92M | 71.56M | -152.55M | -123.28M | -40.30M | 176.11M | 146.78M | -19.70M | -15.45M | — |
| Free Cash Flow | -57.24M | -75.20M | -52.41M | -41.13M | -41.74M | -37.07M | -38.63M | -31.06M | -30.99M | -19.12M | -15.40M | — |
This table shows 12 quarterly periods of Zenas BioPharma's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ZBIO's reporting calendar. What is a cash flow statement?